Nutrigenomics & protein wins
NutraIngredients Europe has announced the 2026 award finalists, spotlighting emerging nutrigenomics and nutrition innovations ahead of the May ceremony in Barcelona. Separately, Zhejiang University researchers reported a membrane‑protein breakthrough that could aid treatments for genetic diseases like Parkinson’s — a noteworthy tie between basic protein science and nutrition‑linked biomedicine. (nutraingredients.com) (eng.belta.by)
The awards ceremony is scheduled for Wednesday, 6 May 2026, when Europe winners will be presented in Barcelona. (nutraingredients-awards.com) This year’s Europe programme features 16 award categories covering ingredients, finished products and company/initiative honours. (nutraingredients-awards.com) The March 25 finalists list includes Veri‑te™ Resveratrol (Valensa International), Cereboost™ (Lallemand Bio‑Ingredients), Levagen®+ (PLT Health Solutions), Magtein (Saanroo/Threotech) and Reducose® (Givaudan) among named ingredient entries. (europesays.com) Zhejiang University’s study, titled “De novo design of GPCR exoframe modulators,” was published in Nature on 16 February 2026. (nature.com) The paper introduces GPCR exoframe modulators (GEMs), de novo, AI‑designed transmembrane proteins that bind GPCR transmembrane domains and were systematically tested on the dopamine D1 receptor as a prototype. (nature.com) ZJU researchers report GEMs are typically 60–80 amino acids long, were designed using a “hallucination‑like” computational pipeline that reduced candidate space to a few hundred molecules for experimental screening, and the work was led by teams under Zhang Yan and Min Zhang. (sciencenet.cn) (zju.edu.cn)
